BioAtla, Inc. (BCAB)
NASDAQ: BCAB · Real-Time Price · USD
3.860
+0.300 (8.43%)
At close: Jun 12, 2026, 4:00 PM EDT
3.760
-0.100 (-2.59%)
After-hours: Jun 12, 2026, 6:42 PM EDT
BioAtla Revenue
BioAtla had revenue of $2.00M in the twelve months ending March 31, 2026, down -81.82% year-over-year. In the year 2025, BioAtla had annual revenue of $2.00M, down -81.82%.
Revenue (ttm)
$2.00M
Revenue Growth
-81.82%
P/S Ratio
3.20
Revenue / Employee
$48,780
Employees
41
Market Cap
6.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.00M | -9.00M | -81.82% |
| Dec 31, 2024 | 11.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 250.00K | -179.00K | -41.72% |
| Dec 31, 2020 | 429.00K | -4.77M | -91.75% |
| Dec 31, 2019 | 5.20M | -5.43M | -51.07% |
| Dec 31, 2018 | 10.63M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evogene | 1.84M |
| PMGC Holdings | 1.27M |
| Can-Fite BioPharma | 405.00K |
| AIM ImmunoTech | 94.00K |
| Cardio Diagnostics Holdings | 16.57K |
BCAB News
- 11 days ago - BioAtla Proxy statement: Proxy filing - Filings
- 11 days ago - BioAtla Proxy statement: Proxy filing - Filings
- 27 days ago - Context Therapeutics enters license agreement amendment with BioAtla - TheFly
- 4 weeks ago - BioAtla Quarterly report: Q1 2026 - Filings
- 2 months ago - BioAtla trading halted, news pending - TheFly
- 2 months ago - BioAtla announces 50-for-1 share consolidation - TheFly
- 2 months ago - BioAtla Announces Share Consolidation - GlobeNewsWire
- 2 months ago - BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - GlobeNewsWire